Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 19/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 18/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013666 | 0.88 | CDK2 (0.40) | CSNK1ECSNK1DCDK12CDK13CCNK | |
| SCHEMBL23497822 | 0.88 | CDK2 (0.40) | CSNK1ECSNK1DCDK12CDK13CCNK | |
| SCHEMBL29788804 | 0.86 | CSNK1E (0.46) | CSNK1ECSNK1DCDK12CDK13CDK4 | |
| SCHEMBL23497496 | 0.86 | CSNK1E (0.46) | CSNK1ECSNK1DCDK12CDK13CDK4 | |
| SCHEMBL23497781 | 0.81 | CSNK1E (0.48) | CSNK1ECSNK1DCDK12CDK13CCNK | |
| SCHEMBL30012915 | 0.81 | CSNK1E (0.48) | CSNK1ECSNK1DCDK12CDK13CCNK | |
| SCHEMBL23508470 | 0.81 | CDK12 (0.47) | CSNK1ECSNK1DCDK12CDK13CCNK | |
| SCHEMBL23508061 | 0.80 | GSK3B (0.38) | GSK3B | |
| SCHEMBL30013305 | 0.80 | CSNK1E (0.42) | CSNK1ECSNK1DCDK12CDK13CCNK | |
| SCHEMBL23508567 | 0.79 | CDK12 (0.44) | CSNK1ECSNK1DCDK12CDK13CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | claimed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | claimed |
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CSNK1E 1596/4885CSNK1D 963/4885CDK12 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.